Advanced International Journal for Research

E-ISSN: 3048-7641   •   Impact Factor: 9.11

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6, Issue 5 (September-October 2025) Submit your research before last 3 days of October to publish your research paper in the issue of September-October.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 6 Issue 5
September-October 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Role and Efficacy of GLP 1 Agonists in the Management of PCOS

Author(s) Dr. Nithisha Chitteti, Dr. Sainath Reddy Ananthula
Country India
Abstract Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder characterised by a constellation of reproductive, metabolic, and hormonal abnormalities. This review evaluates the mechanism of action and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in managing PCOS by analysing relevant studies from multiple databases. The methodological approach involved systematic screening of studies assessing the impact of GLP-1RAs on metabolic parameters and hormonal profiles with comparisons drawn against the standard therapy of Metformin. The selected studies demonstrated that GLP-1RAs effectively improved insulin sensitivity, promoted weight reduction, and enhanced the hormonal profile in women with PCOS. However, variations in study design, sample sizes, and treatment durations posed challenges to direct comparison. Despite promising evidence supporting the metabolic and reproductive benefits of GLP-1RAs in PCOS, long-term data on safety and sustained efficacy remain limited. Further large-scale randomized controlled trials are needed to establish standardized treatment protocols and evaluate the long-term impact of these agents. This review highlights the potential of GLP-1RAs as an emerging therapeutic option in the comprehensive management of PCOS.
Keywords pcos, glp1ra, hyperinsulinemia
Field Medical / Pharmacy
Published In Volume 6, Issue 4, July-August 2025
Published On 2025-08-05
DOI https://doi.org/10.63363/aijfr.2025.v06i04.1084
Short DOI https://doi.org/g9zx7t
View / Download PDF File

Share this



E-ISSN 3048-7641
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

AIJFR DOI prefix is
10.63363/aijfr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About AIJFR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-91574-37535 editor@aijfr.com